IP Library › Patent Application 15304179
Patent Application
App. No. 15/304,179

METHODS OF TREATMENT OF C. DIFFICILE SPORES WITH RAMOPLANIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/304,179
Abstract

The present disclosure relates generally to methods of treatment of Clostridium difficile -associated disorders and/or C. difficile spores in the gastrointestinal tract by administering ramoplanin or a pharmaceutical formulation thereof, pharmaceutical compositions comprising ramoplanin, and therapeutic uses thereof in treating Clostridium difficile -associated disorders and/or C. difficile spores.

Claims (20)

1 . A method of treating a patient with a C. difficile -associated condition, said method comprising administering to said patient ramoplanin in an amount and for a duration effective to treat said condition, wherein said method is effective for reducing the population of C. difficile and rendering C. difficile spores non-viable, wherein the exosporium is the target for ramoplanin binding.

2 . A method of rendering C. difficile spores non-viable, the method comprising administering ramoplanin to a patient in need thereof.

3 . A method of preventing a relapse of a C. difficile -associated disorder in a patient in need thereof, the method comprising administering ramoplanin to the patient.

4 . The method according to claim 1 , wherein the patient is at risk for relapse of a C. difficile -associated condition.

5 . The method according to claim 1 , wherein the patient was treated with at least one antimicrobial prior to administration of ramoplanin.

6 . The method according to claim 5 , wherein the at least one antimicrobial is ineffective for eradicating or eliminating C. difficile spores, or rendering C. difficile spores non-viable.

7 . The method according to claim 5 , wherein the at least one antimicrobial did not eradicate or eliminate C. difficile spores in the patient, or render C. difficile spores non-viable in the patient.

8 . The method according to claim 1 , wherein the patient is at risk for further infection.

9 . The method according to claim 1 , wherein the method limits resistance to at least one antimicrobial by limiting residual C. difficile population density.

10 . A method of treating a patient with a C. difficile -associated condition according to claim 1 , wherein the method alleviates CDI institutional outbreaks through targeted infection control prophylaxis by analyzing a patient's stool to test for C. difficile bacteria or spores and providing targeted prophylaxis of an identified carrier.

11 . The method according to claim 1 , wherein the ramoplanin is administered as a pharmaceutical composition comprising ramoplanin.

12 . The method according to claim 1 , wherein the ramoplanin or pharmaceutical composition thereof is administered orally.

13 . The method according to claim 2 , wherein the patient is at risk for relapse of a C. difficile -associated condition, or was treated with at least one antimicrobial prior to administration of ramoplanin.

14 . The method according to claim 13 , wherein the at least one antimicrobial is ineffective for eradicating or eliminating C. difficile spores, or rendering C. difficile spores non-viable, or the at least one antimicrobial did not eradicate or eliminate C. difficile spores in the patient, or render C. difficile spores non-viable in the patient.

15 . The method according to claim 2 , wherein the ramoplanin is administered as a pharmaceutical composition comprising ramoplanin.

16 . The method according to claim 2 , wherein the ramoplanin or pharmaceutical composition thereof is administered orally.

17 . The method according to claim 3 , wherein the patient is at risk for relapse of a C. difficile -associated condition, or was treated with at least one antimicrobial prior to administration of ramoplanin.

18 . The method according to claim 18 , wherein the at least one antimicrobial is ineffective for eradicating or eliminating C. difficile spores, or rendering C. difficile spores non-viable, or the at least one antimicrobial did not eradicate or eliminate C. difficile spores in the patient, or render C. difficile spores non-viable in the patient.

19 . The method according to claim 3 , wherein the ramoplanin is administered as a pharmaceutical composition comprising ramoplanin.

20 . The method according to claim 3 , wherein the ramoplanin or pharmaceutical composition thereof is administered orally.